In Vivo Retargeting of Poly(beta aminoester) (OM‐PBAE) Nanoparticles is Influenced by Protein Corona

One of the main bottlenecks in the translation of nanomedicines from research to clinics is the difficulty in designing nanoparticles actively vectorized to the target tissue, a key parameter to ensure efficacy and safety. In this group, a library of poly(beta aminoester) polymers is developed, and it is demonstrated that adding specific combinations of terminal oligopeptides (OM-PBAE), in vitro transfection is cell selective. The current study aims to actively direct the nanoparticles to the liver by the addition of a targeting molecule. To achieve this objective, retinol, successfully attached to OM-PBAE, is selected as hepatic targeting moiety. It is demonstrated that organ biodistribution is tailored, achieving the desired liver accumulation. Regarding cell type transfection, antigen presenting cells in the liver are those showing the highest transfection. Thanks to proteomics studies, organ but not cellular biodistribution can be explained by the formation of differential protein coronas. Therefore, organ biodistribution is governed by differential protein corona formed when retinol is present, while cellular biodistribution is controlled by the end oligopeptides type. In summary, this work is a proof of concept that demonstrates the versatility of these OM-PBAE nanoparticles, in terms of the modification of the biodistribution of OM-PBAE nanoparticles adding active targeting moieties.

[1]  B. Chandu,et al.  Erythrocytes as Carrier for Drugs, Enzymes and Peptides , 2012 .

[2]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[3]  Pere Dosta,et al.  Oligopeptide-terminated poly(β-amino ester)s for highly efficient gene delivery and intracellular localization. , 2014, Acta biomaterialia.

[4]  Svetlana Gelperina,et al.  Adsorption of plasma proteins on uncoated PLGA nanoparticles. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  B. Trump,et al.  Mouse liver cell culture , 1981, In Vitro.

[6]  Morteza Mahmoudi,et al.  Protein-Nanoparticle Interactions , 2013 .

[7]  C. Solans,et al.  Interactions of PLGA nanoparticles with blood components: protein adsorption, coagulation, activation of the complement system and hemolysis studies. , 2015, Nanoscale.

[8]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[9]  Pere Dosta,et al.  Stable and efficient generation of poly(β-amino ester)s for RNAi delivery , 2018 .

[10]  E. Coche,et al.  Serum fetuin-A levels are associated with vascular calcifications and predict cardiovascular events in renal transplant recipients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[11]  Jörg Huwyler,et al.  Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Y. Yamaoka,et al.  Enrichment of hepatic progenitor cells from adult mouse liver , 2003, Hepatology.

[13]  Takashi Yamamoto,et al.  SERIES : Hepatic sinusoidal cells in liver physiology and pathology , 2004 .

[14]  Marina A Dobrovolskaia,et al.  Current understanding of interactions between nanoparticles and the immune system. , 2016, Toxicology and applied pharmacology.

[15]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[16]  Kenneth A. Dawson,et al.  Protein–Nanoparticle Interactions , 2008, Nano-Enabled Medical Applications.

[17]  Scott E. McNeil,et al.  Handbook of Immunological Properties of Engineered Nanomaterials , 2016 .

[18]  A. Cascante,et al.  mRNA Delivery System for Targeting Antigen‐Presenting Cells In Vivo , 2018, Advanced healthcare materials.

[19]  W. Saltzman,et al.  Cellular distribution of injected PLGA-nanoparticles in the liver. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[20]  Q. Huo,et al.  Dynamic light scattering for gold nanorod size characterization and study of nanorod–protein interactions , 2012, Gold Bulletin.

[21]  I. Delfino,et al.  Optical investigation of the electron transfer protein azurin-gold nanoparticle system. , 2009, Biophysical chemistry.

[22]  Volker Rasche,et al.  Cargo-influences on the biodistribution of hollow mesoporous silica nanoparticles as studied by quantitative 19F-magnetic resonance imaging. , 2017, Journal of colloid and interface science.

[23]  N. Packer,et al.  Influence of surface chemistry on the formation of a protein corona on nanodiamonds , 2019, Journal of Materials Chemistry B.

[24]  Sara Linse,et al.  Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles , 2007, Proceedings of the National Academy of Sciences.

[25]  M. Green,et al.  Vitamin A metabolism: new perspectives on absorption, transport, and storage. , 1991, Physiological reviews.

[26]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[27]  Mark W. Tibbitt,et al.  Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes , 2017, Advanced materials.

[28]  Pere Dosta,et al.  Surface charge tunability as a powerful strategy to control electrostatic interaction for high efficiency silencing, using tailored oligopeptide-modified poly(beta-amino ester)s (PBAEs). , 2015, Acta biomaterialia.

[29]  S. K. Sundaram,et al.  Adsorbed proteins influence the biological activity and molecular targeting of nanomaterials. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[31]  M. Schilsky,et al.  Inherited metabolic liver disease , 2003, Current opinion in gastroenterology.

[32]  W. Blaner Retinol-binding protein: the serum transport protein for vitamin A. , 1989, Endocrine reviews.

[33]  Cristina Fornaguera,et al.  Personalized Nanomedicine: A Revolution at the Nanoscale , 2017, Journal of personalized medicine.

[34]  M. Budoff,et al.  Fetuin-A, glycemic status, and risk of cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. , 2016, Atherosclerosis.

[35]  David Victor,et al.  Hepatocellular carcinoma: a review , 2016, Journal of hepatocellular carcinoma.

[36]  Patrick Couvreur,et al.  Nanotheranostics for personalized medicine. , 2016, Advanced drug delivery reviews.

[37]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[38]  A. Blumenthal,et al.  Efficient Biodistribution and Gene Silencing in the Lung epithelium via Intravenous Liposomal Delivery of siRNA , 2013, Molecular therapy. Nucleic acids.

[39]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[40]  Parag Aggarwal,et al.  Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. , 2009, Advanced drug delivery reviews.

[41]  J. Benoit,et al.  Design and production of nanoparticles formulated from nano-emulsion templates-a review. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[42]  Junji Kato,et al.  Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone , 2008, Nature Biotechnology.

[43]  M. Trauner,et al.  Cancer and liver cirrhosis: implications on prognosis and management , 2016, ESMO Open.

[44]  Ruth Duncan,et al.  Development of HPMA copolymer-anticancer conjugates: clinical experience and lessons learnt. , 2009, Advanced drug delivery reviews.

[45]  N. Artzi,et al.  Hydrogel Doped with Nanoparticles for Local Sustained Release of siRNA in Breast Cancer , 2015, Advanced healthcare materials.

[46]  Mauro Ferrari,et al.  Contribution of Kupffer cells to liposome accumulation in the liver. , 2017, Colloids and surfaces. B, Biointerfaces.

[47]  Cristina Fornaguera,et al.  Methods for the In Vitro Characterization of Nanomedicines—Biological Component Interaction , 2017, Journal of personalized medicine.

[48]  Jonathan L. Kirschman,et al.  Arginine‐Rich Peptide‐Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide , 2017, Advanced healthcare materials.

[49]  L. Gonçalves,et al.  Improved isolation of murine hepatocytes for in vitro malaria liver stage studies , 2007, Malaria Journal.

[50]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[51]  J. George,et al.  The use of nanoparticles to deliver nitric oxide to hepatic stellate cells for treating liver fibrosis and portal hypertension. , 2015, Small.

[52]  Tai-Long Pan,et al.  The impact of retinol loading and surface charge on the hepatic delivery of lipid nanoparticles. , 2016, Colloids and surfaces. B, Biointerfaces.

[53]  Kenneth A Dawson,et al.  Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. , 2013, Journal of the American Chemical Society.

[54]  Warren C W Chan,et al.  Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. , 2012, Chemical Society reviews.

[55]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[56]  Arezou A Ghazani,et al.  Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. , 2006, Nano letters.

[57]  Iseult Lynch,et al.  Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. , 2011, Journal of the American Chemical Society.

[58]  Morteza Mahmoudi,et al.  Nanoparticle and Protein Corona , 2013 .

[59]  J. Pourchez,et al.  Preferential binding of positive nanoparticles on cell membranes is due to electrostatic interactions: A too simplistic explanation that does not take into account the nanoparticle protein corona. , 2017, Materials science & engineering. C, Materials for biological applications.

[60]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[61]  A. Lavasanifar,et al.  Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. , 2011, Advanced drug delivery reviews.

[62]  H. Rehage,et al.  Dynamic light-scattering analysis of the electrostatic interaction of hexahistidine-tagged cytochrome P450 enzyme with semiconductor quantum dots. , 2006, Chemphyschem : a European journal of chemical physics and physical chemistry.